title: Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension.
authors.forename: Ori
authors.initials: O
authors.lastname: Ben-Yehuda
authors.forename: David
authors.initials: D
authors.lastname: Pizzuti
authors.forename: Andrea
authors.initials: A
authors.lastname: Brown
authors.forename: Marcus
authors.initials: M
authors.lastname: Littman
authors.forename: Hunter
authors.initials: H
authors.lastname: Gillies
authors.forename: Noreen
authors.initials: N
authors.lastname: Henig
authors.forename: Tobias
authors.initials: T
authors.lastname: Peschel
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001219:Aspartate Aminotransferases / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000201:enzymology / Q000453:epidemiology / Q000209:etiology*; D004334:Drug Administration Schedule; D065130:Endothelin A Receptor Antagonists; D016232:Endothelins / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D015994:Incidence; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology / Q000503:physiopathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010666:Phenylpropionates / Q000008:administration & dosage* / Q000009:adverse effects*; D011724:Pyridazines / Q000008:administration & dosage* / Q000009:adverse effects*; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
chemical_list: D000959:Antihypertensive Agents; D065130:Endothelin A Receptor Antagonists; D016232:Endothelins; D010666:Phenylpropionates; D011724:Pyridazines; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; C467894:ambrisentan